Ocular Symptoms Are Persistent in AChR Antibody‐Positive Generalized Myasthenia Gravis: A Single Center Study Quantified by an Ocular Index
Acta Neurologica Scandinavica · 2026-01 · 2026 (1)
DOI: 10.1155/ane/5560889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neurologica Scandinavica, online erschienen am 23.03.2026. Verfasst von Xicheng Li und 3 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Shenkang Hospital Development Center.
Abstract (Originalsprache)
Introduction/Aims Ocular symptoms are prevalent and exacerbate the disease burden among patients with myasthenia gravis (MG). However, their detection and therapeutic strategies are frequently neglected. The aim of this study is to demonstrate the relative burden of ocular symptoms throughout the treatment course of MG.
Methods
We conducted a retrospective, longitudinal registry‐based study at Huashan Hospital, Fudan University, involving 93 treatment‐naive patients with acetylcholine receptor antibody‐positive (AChR+) MG, and collected their clinical manifestations and pharmacological treatment measures. Myasthenia Gravis Ocular Index (MGOI) of Myasthenia Gravis Activities of Daily Living (MG‐ADL), quantitative myasthenia gravis (QMG), myasthenia gravis composite (MGC), and Myasthenia Gravis Quality of Life 15‐item (MG‐QoL‐15) at baseline and at the 2‐year follow‐up, as well as ΔMGOI, the difference between each pair of MGOIs, were calculated. And a subgroup of 46 patients from this cohort with a follow‐up duration of 4 years was utilized for long‐term validation.
Results
The study found that despite a decline in both ocular and nonocular scores, MGOI for MG scales (ΔMGOI‐MG‐ADL: 0.10 ± 0.35, p < 0.001; ΔMGOI‐QMG: 0.04 ± 0.27, p > 0.05; ΔMGOI‐MGC: 0.15 ± 0.35, p < 0.001; ΔMGOI‐QoL‐15: 0.07 ± 0.29, p < 0.05) increased in the 2‐year follow‐up, indicating a relative escalating ocular burden compared with other muscle groups. A relative deceleration in MGOI change was observed between the second and the third follow‐ups (in the second year). For MGOI‐MGC, nonsteroid immunosuppressants (ΔMGOI‐MGC: 0.20 ± 0.37, p < 0.05) or prednisone treatment (ΔMGOI‐MGC: 0.16 ± 0.35, p < 0.05) were correlated with a more significant elevation. The long‐term follow‐up subcohort (0–4 years) validated the persistent increase in MGOI‐ADL (0.18 ± 0.42, p < 0.05) and MGOI‐MGC (0.19 ± 0.37, p < 0.001).
Discussion
Ocular symptoms are persistent in patients with MG, which might be related to the anatomical and physiological characteristics of extraocular muscles and their responsiveness to treatment.
Förderung
- National Natural Science Foundation of China
- Shanghai Shenkang Hospital Development Center
Zitieren
APA
Li, X., Zhong, H., Luo, S., & Zhao, C. (2026). Ocular Symptoms Are Persistent in AChR Antibody‐Positive Generalized Myasthenia Gravis: A Single Center Study Quantified by an Ocular Index. Acta Neurologica Scandinavica, 2026(1). https://doi.org/10.1155/ane/5560889
Vancouver
Li X, Zhong H, Luo S, Zhao C. Ocular Symptoms Are Persistent in AChR Antibody‐Positive Generalized Myasthenia Gravis: A Single Center Study Quantified by an Ocular Index. Acta Neurologica Scandinavica. 2026;2026(1). doi:10.1155/ane/5560889
BibTeX
@article{Li2026,
author = {Li, Xicheng and Zhong, Huahua and Luo, Sushan and Zhao, Chongbo},
title = {Ocular Symptoms Are Persistent in AChR Antibody‐Positive Generalized Myasthenia Gravis: A Single Center Study Quantified by an Ocular Index},
journal = {Acta Neurologica Scandinavica},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ane/5560889}
}
EUVIMED